SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-19-013939
Filing Date
2019-04-30
Accepted
2019-04-30 06:04:11
Documents
6
Period of Report
2019-06-12
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A reta-def14a_20190612.htm DEF 14A 1030150
2 GRAPHIC gelmx4yxxiza000004.jpg GRAPHIC 62915
3 GRAPHIC gelmx4yxxiza000005.jpg GRAPHIC 35109
4 GRAPHIC gelmx4yxxiza000002.jpg GRAPHIC 1206
5 GRAPHIC gelmx4yxxiza000001.jpg GRAPHIC 6386
6 GRAPHIC gelmx4yxxiza000003.jpg GRAPHIC 6515
  Complete submission text file 0001564590-19-013939.txt   1186356
Mailing Address 2801 GATEWAY DRIVE SUITE 150 IRVING TX 75063
Business Address 2801 GATEWAY DRIVE SUITE 150 IRVING TX 75063 972-865-2206
REATA PHARMACEUTICALS INC (Filer) CIK: 0001358762 (see all company filings)

IRS No.: 113651945 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37785 | Film No.: 19778193
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences